Therapeutic Management of Chronic Hepatitis B in Clinical Practice
Authors:
- Edoardo G. GianniniEdoardo G. Giannini
- Simona MarencoSMSimona Marenco
- Silvia BoniSBSilvia Boni
- Andrea BeltrameABAndrea Beltrame
- Laura A. NicoliniLNLaura A. Nicolini
- Lucia TaramassoLTLucia Taramasso
- Marcello FeasiMFMarcello Feasi
- Alessandro GrassoAGAlessandro Grasso
- Pasqualina De LeoPLPasqualina De Leo
- Gianfranco PercarioGPGianfranco Percario
- Valentina BartolacciVBValentina Bartolacci
- Stefania ArtioliSAStefania Artioli
- 1 March 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 49 (3) , 228-234
Abstract
To characterize the clinical and treatment pattern in a large population of hepatitis B virus (HBV) patients managed at tertiary referral centers in clinical practice. Successful treatment, either with interferon (IFN) or nucleos(t)ide analogs (NUCs), of chronic HBV infection is associated with improved long-term patient outcome. However, in clinical practice, the actual management of these patients is not well characterized, and data regarding treatment pattern in this setting are lacking. In this cross-sectional study, we evaluated 505 patients chronically infected with HBV alone and who had at least 1-year follow-up. We assessed indication to, rate of, and type of treatment as well as the characteristics of treated patients. Overall prevalence of positivity for HBe antigen was 19.3%, and the majority of patients had chronic hepatitis (47.5%). Non-Italian patients represented approximately one third of the population (27.1%). Among patients with indication to antiviral therapy (n=318), treatment was actually carried out in 264 patients (83.0%), prevalently with NUCs (65.9%). IFN-treated patients were younger (P<0.001), more frequently male (P=0.025) and HBeAg positive (P=0.003), and less frequently cirrhotics (P<0.001) as compared with patients treated with NUCs. In a geographical area with a low positivity for HBe antigen, antiviral therapy is actually carried out in the majority of patients who have indication to treatment, prevalently with NUCs, whereas IFN treatment is more frequently carried out in young, HBe antigen-positive patients who do not have advanced liver disease.Keywords
This publication has 26 references indexed in Scilit:
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- A Significant Proportion of Patients With Chronic Hepatitis B Who are Candidates for Antiviral Treatment are UntreatedJournal of Clinical Gastroenterology, 2009
- Side effects of long-term oral antiviral therapy for hepatitis B #Hepatology, 2009
- Management of hepatitis BHepatology, 2007
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006
- Characteristics of liver cirrhosis in Italy: results from a multicenter national studyDigestive and Liver Disease, 2004
- The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in ItalyJournal of Hepatology, 2000
- The long-term course of chronic hepatitis BHepatology, 1999
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997
- Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis BNew England Journal of Medicine, 1996